Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Johnson & Johnson Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Johnson & Johnson şirketinin kazançları yıllık ortalama -1.7% oranında azalırken, Pharmaceuticals sektörünün kazançları yıllık 0.3% oranında azalan oldu. Gelirler yıllık ortalama 0.7% oranında artan oldu. Johnson & Johnson şirketinin öz sermaye getirisi 22.9% olup, net marjı 18.9% dir.

Anahtar bilgiler

-1.7%

Kazanç büyüme oranı

-0.6%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	6.0%
Gelir büyüme oranı	0.7%
Özkaynak getirisi	22.9%
Net Marj	18.9%
Sonraki Kazanç Güncellemesi	15 Oct 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Jul 03

Gelir ve Gider Dağılımı

Johnson & Johnson nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NYSE:JNJ Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	86,576	16,382	21,050	14,909
31 Mar 24	85,648	17,072	20,640	15,172
31 Dec 23	85,159	13,326	20,166	15,085
01 Oct 23	83,703	12,421	19,738	14,315
02 Jul 23	82,348	12,422	19,323	14,353
02 Apr 23	77,458	10,730	17,993	14,128
01 Jan 23	79,990	16,370	19,078	14,135
02 Oct 22	84,855	17,879	21,037	15,145
03 Jul 22	88,197	17,236	22,197	15,082
03 Apr 22	94,880	19,830	24,430	14,998
02 Jan 22	78,740	17,801	19,506	14,277
03 Oct 21	91,446	17,880	23,364	14,026
04 Jul 21	89,190	17,767	22,852	13,444
04 Apr 21	84,214	15,115	21,817	12,757
03 Jan 21	82,584	14,714	21,731	12,159
27 Sep 20	80,856	16,986	21,681	11,359
28 Jun 20	80,503	15,185	21,625	11,118
29 Mar 20	82,729	17,166	22,185	11,077
29 Dec 19	82,059	15,119	21,885	11,355
29 Sep 19	81,706	14,151	21,957	11,347
30 Jun 19	81,325	16,332	22,191	11,256
31 Mar 19	81,593	14,679	22,437	11,229
30 Dec 18	81,581	15,297	22,540	10,775
30 Sep 18	81,382	1,542	22,454	11,194
01 Jul 18	80,684	1,372	22,300	11,271
01 Apr 18	78,693	1,245	21,758	10,928
31 Dec 17	76,450	1,300	21,520	10,594
01 Oct 17	74,361	15,827	20,600	9,591
02 Jul 17	72,531	16,335	20,012	9,184
02 Apr 17	72,174	16,505	20,020	9,152
01 Jan 17	71,890	16,540	19,793	9,143
02 Oct 16	71,595	15,941	20,527	9,319
03 Jul 16	70,877	15,027	20,836	9,295
03 Apr 16	70,182	15,546	21,044	9,160
03 Jan 16	70,074	15,409	21,203	9,046
27 Sep 15	70,517	14,715	21,134	8,817
28 Jun 15	71,882	16,106	21,521	8,686
29 Mar 15	73,590	15,916	21,618	8,562
28 Dec 14	74,331	16,323	21,954	8,494
28 Sep 14	74,232	17,321	22,049	8,270
29 Jun 14	73,340	15,554	21,895	8,289
30 Mar 14	71,722	15,061	21,790	8,230
29 Dec 13	71,312	13,831	21,830	8,183

Kaliteli Kazançlar: JNJ büyük bir tek seferlik zarar ile $7.0B, 30th June, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: JNJ 'nin mevcut net kar marjları (18.9%) geçen yılın (15.1%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: JNJ şirketinin kazançları son 5 yılda yılda 1.7% oranında azaldı.

Büyüme Hızlandırma: JNJ 'un son bir yıldaki kazanç büyümesi ( 32.3% ) 5 yıllık ortalamasını (yıllık -1.7% ) aşıyor.

Kazançlar vs. Sektör: JNJ geçen yılki kazanç büyümesi ( 32.3% ) Pharmaceuticals sektörünün 13% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: JNJ 'nin Özsermaye Getirisi ( 22.9% ) yüksek olarak değerlendiriliyor.

Johnson & Johnson Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Recent updates

Johnson & Johnson Announces the Results of A Landmark Real-World, Head-To-Head Study Showing That Erleada (Apalutamide)

Johnson & Johnson Files for U.S. FDA Approval of DARZALEX FASPRO-Based Quadruplet Regimen for Newly Diagnosed Multiple Myeloma Patients for Whom Transplant Is Not Planned

Johnson & Johnson Announces Data from Three Studies Highlighting Clinical Efficacy of Darzalex® (Daratumumab) and Darzalex Faspro in Maintenance Regimens

Johnson & Johnson: A Sell-Rated Dividend King

Johnson & Johnson Announces Interim Data from the Ongoing Phase 2 Sunrise-4 Study Showing Neoadjuvant Treatment with Investigational Tar-200 Plus Cetrelimab

Johnson & Johnson Announces Updated Results from the Phase 3 Mariposa-2 Study Which Showed Rybrevant (Amivantamab-Vmjw)

Johnson & Johnson Announces the Retirement of D. S. Davis as Director and Committee Changes

Why Investors Shouldn't Be Surprised By Johnson & Johnson's (NYSE:JNJ) P/E

Johnson & Johnson to Report Q4, 2024 Results on Jan 22, 2025

Johnson & Johnson Seeks First Approval of Nipocalimab to Treat Broadest Population Living with Antibody Positive Generalized Myasthenia Gravis

Johnson & Johnson Announces Executive Changes

We Think Johnson & Johnson (NYSE:JNJ) Can Stay On Top Of Its Debt

Johnson & Johnson: Don't Bet Against Double Compounding

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Rybrevant® (Amivantamab-Vmjw) Plus Lazcluze™ (Lazertinib)

Upcoming dividend of US$1.24 per share

Johnson & Johnson Announces Results from the Phase 2 Open-Label UNITY Study of Nipocalimab for the Treatment of Alloimmunized Pregnant Individuals

Johnson & Johnson Announces Darzalex Faspro® (Daratumumab and Hyaluronidase-Fihj)-Based Quadruplet Regimen Approved in the U.S. for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible

Consensus EPS estimates fall by 10%

Johnson & Johnson Seeks U.S. FDA Approval of Spravato (Esketamine) as the First and Only Monotherapy for Adults with Treatment-Resistant Depression

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2: Robust New Product Pipeline

Johnson & Johnson Announces Quarterly Cash Dividend for Third Quarter of 2024, Payable on September 10, 2024

Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality

Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction

Johnson & Johnson Announces Positive Results from Prespecified Second Interim Analysis of the Phase 3 CARTITUDE-4 Study Evaluating CARVYKTI

Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.

Beasley Allen and Levin Papantonio Announces Class Action Lawsuit Against Johnson & Johnson

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin